With the disease burden expected to exceed 152 million by 2050 according to World Alzheimer Report 2018, much effort is now directed towards developing new drugs that slow down or prevent AD by affecting amyloid-beta (Aβ) processing pathway and tau pathology [22, 28]. This evidence concerns the gene MAPT and Alzheimer disease.